PRAKASH PEDDI, MD, MS. 

Hematology and Oncology Associates,

2600 Kings Highway, Suite 340 Shreveport LA 71103.

Phone : (318) 212-8620 ; Fax : (318) 212-8687 

Email : [email protected] 

_____________________________________________________________________________________________

EDUCATION: 

• 1996 - 2002: MBBS, Kakatiya Medical College, Warangal, India.

POST GRADUATE EDUCATION AND TRAINING: 

• 2010 - 2013: Clinical Fellow, Hematology and Oncology, Louisiana State University- HSC - Shreveport, LA.
• 2008 - 2010: Resident, Internal Medicine Residency, Louisiana State University- HSC - Shreveport, LA.
• 2007 - 2008: Intern, Internal Medicine Residency, Louisiana State University- HSC - Shreveport, LA.
• 2004 - 2007: Master of Science: Molecular Biology and Biotechnology, East Carolina University, NC. 

CERTIFICATIONS: 

• 2010: Diplomate in Internal Medicine by American Board of Internal Medicine.
• 2014: Board Certification in Medical Oncology by American Board of Internal Medicine. 

MEDICAL LICENSURES:  

• 2007 – Present: Active: Louisiana.

ACADEMIC, ADMINISTRATIVE and COMMITTEE APPOINTMENTS: 

• 2013 - 2018: Asst. Professor of Medicine, Hematology and Oncology, LSUHSC, Shreveport, LA.
• 2014 - 2018: Present: Director of Sarcoma Research, FWCC, Shreveport, LA. 
• 2014 - 2018: Present: Associate Director of Clinical Operations, FWCC, Shreveport, LA.
• 2014 - 2018: 2018: Associate Director of Breast Cancer Research, FWCC, Shreveport, LA.
• 2014 - 2015: Director, Adult Sickle Cell Service, FWCC, Shreveport, LA.

• 2013 - 2018: Cancer Committee member: LSU-Health Sciences Center, Shreveport, LA. 
• 2013 - 2018: Hormone Related Malignancy Group, LSU-Health Sciences Center, Shreveport, LA.
• 2013 - 2018: Institutional Review Board member, LSU-Health Sciences Center, Shreveport, LA
• 2013 - 2018: Breast Cancer Focus Group, LSU-Health Sciences Center, Shreveport, LA.  

CONTINUING MEDICAL EDUCATION PROGRAM

• 2023: Breast Cancer Review; WKHS, Shreveport
• 2016: Faculty member for the development of eLearning Course, ASCO.  
• 2016: Adjuvant Endocrine Therapy in Premenopausal Breast Cancer Patients: Tumor Board Course
• 2016: Internal Medicine Board Review Courses, 15^th Ann. Intensive Review of Int. Med. Shreveport, LA. 
• 2016: Oncology for Internists/ Oncological Emergencies 
• 2013: 2014: Grand-Rounds, Feist Weiller Cancer Center, LSU- Health Sciences Center, Shreveport, LA. 
• 2012: Management of Soft Tissue Sarcoma / 2013: Role of Tyrosine Kinase Inhibitors in Thyroid Cancer/
• 2014: HER2 Positive Metastatic Breast Cancer Management  

PROFESSIONAL SOCIETY MEMBERSHIP 

• 2010 - Present: American Society of Clinical Oncology 
• 2010 – 2013: American Society of Hematology 
• 2007 – 2020: American College of Physicians 
• 2004 - 2007: Radiation Research Society 
• 2004 - 2010: American Association of Cancer Research 
• 2013 - 2018: Member of SWOG and Investigator with Gulf States Minority based NCORP.  

WORK/RESEARCH EXPERIENCE 

• 07/2012 - 06/2013: Chief Fellow, Hematology and Oncology, LSU Health Shreveport, LA. 
• 07/2009 - 06/2010: Chief Resident, Internal Medicine, LSU Health, Shreveport, LA. 
• 08/2004 - 04/2007: Anatomy & Physiology Lab Instructor & TA, Dept. of Biology, ECU, Greenville, NC.
• 08/2004 - 04/2007: Graduate student- Molecular Biology, Dept. of Biology, ECU, Greenville, NC.
• 08/2003 - 11/2003: Research Project Trainee, Shanta Biotechnics R&D center, Hyderabad, India. 

JOURNAL REVIEWER EXPERIENCE: 

• 2015 - Present: Peer Reviewer: Clinical Medicine Insights: Oncology. 
• 2015 - 2018: Peer Reviewer: British Medical Journal. 
• 2015 - 2018: Oncological malignancy Breast section co-editor.
• 2015 - 2018: Member of Editorial board. Advances in Modern Oncology Research. 
• 2016 - 2018: Peer Reviewer: Journal of Cell Death 
• 2016 - Present: Peer Reviewer: Clinical Medicine Reviews in Oncology

AWARDS AND HONORS 

• 2016 Healer Award: LSU Health, Shreveport.  

TEACHING ACTIVITIES

MEDICAL STUDENT PRECEPTORSHIP

• 2010 - 2018: H&P Preceptorship for Medical Students 
• 2013 - 2014: FLAG Leader for facilitated learning 

MEDICAL STUDENT AND INTERNAL MEDICINE LECTURES 

• 2007: Focal Segmental Glomerulonephritis 
• 2010: Role of GLP-1 in Type-2 Diabetes Mellitus 2010 
• 2013 - 2018: Iron Transportation 
• 2013 - 2018: Anemia: Student Lectures 
• 2013 - 2018: B12 and Folate Deficiency Student/Resident Lectures
• 2013 - 2018: Brest Cancer Review for Internal Medicine residents 
• 2013 - 2018: Morning Rounds lectures, during ward rotations. 

INTENSIVE CARE UNIT STAFF/RESIDENT /FELLOWS CORE CURRICULUM LECTURES

• 2015: Oncology for Intensivists.  

ONCOLOGY FELLOW LECTURES: 2013- 2018 

• • Basics of Breast Cancer Diagnosis, Pathology.  
  • Early Breast Cancer Management 
  • Breast Cancer Screening / Diagnosis  
  • Role of neoadjuvant therapy in Breast Cancer 
  • Management of Metastatic HER2 positive Breast Cancer 
  • Management of Locally Advanced Breast Cancer 
  • Management of Triple Negative Breast Cancers 
  • Soft Tissue Sarcoma- Basics and Molecular Biology 
  • Management of Metastatic Soft Tissue Sarcoma  

TUMOR BOARD PARTICIPATION

• 2014 - 2018: Neuro-Oncology Tumor Board Participation once every 2 weeks
• 2013 - 2018: Hepato-Pancreato-Biliary (HPB) Tumor board every week
• 2010 - 2018: Surgical Oncology – Breast tumor board participation every week 
• 2018 - Present: Organizing and conducting Breast Tumor board at WKHS.

PEER REVIEWED PUBLICATIONS: 

1. Avery D, Singh V,Cupp J, Peddi P. Metastatic breast cancer presenting as an incidental colon polyp on screening colonoscopy. BMJ Case Rep. PMID: 40467076
2. Grivas P, Khaki AR, Wise-draper TM, French B, Peddi P et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium; Ann Oncol 2021: PMID 33746047
3. Thompson MA, Henderson JP, Shah PK, Peddi P et al; Association of Convalescent Plasma Therapy with Survival in Patients with Hematological Cancers and COVID-19; JAMA Oncology 2021: 34137799 
4. Abidi M, Aboulafia DM, Accordino MK, Acoba JD, Peddi P et al; A systemic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19; CC19 Governance, Protocol, and Quality Assurance; Cancer Cell 2020: 331761603.
5. Kuderer NM, Choueiri, TK, Shah DP, Rubinstein SM, Peddi P et al; Clinical Impact of COVID-19 on patients with cancer (CC19): a cohort study: Lancet 2020; PMID: 32473681 
6. Pathan S, Benzar T, Master S, Peddi P; Iatrogenic Constipation from Barium Blockade; A Case Report: Clin Case Rep 2019: PMID; 31428392 
7. Zhou M, Peddi P, Chu QD. Can Radiation therapy adequately address positive surgical margins in women ≥70 years with stage I, estrogen receptor positive breast cancer? Anticancer Research: In Print: 9394-Z, 2018. 
8. Peddi P, Master RS, Dwary DD, Ravipati PH, Patel A, Katikaneni KP, Shi R, Burton VG, Chu DQ: Utility of Routine Pre-Treatment Evaluation of Left Ventricular Ejection Fraction in Breast Cancer Patients Receiving Anthracyclines. The Breast Journal. In print: 25 (5) Issue. TBJ-00030. 2018 
9. Chu QD, Zhou M, Peddi P, Medeiros KL, Wu XC. Outcomes in real-world practice are different than cooperative trial for elderly patients with early breast cancer treated with adjuvant radiation therapy. Surgery 2018, PMID 29525735.
10. Sommerhalder D, Takalkar AM, Shackelford R, Peddi P. Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review. Clin Case Rep 2017, PMID: 29207685. 
11. Dwary AD, Master S, Patel A, Cole C, Mansour R, Mills G, Koshy N, Peddi P, Burton G, Hammoud D, Beedupalli K.  Excellent response to chemotherapy post immunotherapy. Oncotarget 2017, PMID: 29207685 
12. Chu Q, Zhou M, Medeiros K, Peddi P, Wu XC. Impact of CALGB 9343 Trial and Sociodemographic Variation on Adjuvant Radiation Therapy Practice Patterns in Elderly Women (≥70 years) with Stage I, Estrogen Receptor Positive Breast Cancer:  Analysis of the National Cancer Data Base. Anticancer Research 2017, PMID: 28982874 
13. Chu Q, Peddi P, Medeiros K, Zibari G, Wu XC, Shokouh Amiri, H, Zhou M. Influence of Facility type on Survival Outcomes for Pancreatectomy for Pancreatic Adenocarcinoma. Accepted. HPB 2017, PMID: 28967535. 
14. Cingam SR, Koshy N, Veillon D, Peddi P. Reversal of isolated 20q deletion with vitamin B12 replacement in a patient with pernicious anemia. BMJ case reports. 2017, PMID: 28275019. 
15. Cingam SR, Al Shaarani M, Takalkar A, Peddi P. Follicular dendritic sarcoma masquerading as fibrosing mediastinitis. BMJ case reports 2017, PMID: 28611161. 
16. Anand K, Cingam S, Peddi P. Recurrent Malignant Melanoma Presenting as Isolated Pleural Metastases in a Patient with Chronic Lymphocytic Leukemia. Case Reports in Oncology 2017, PMID: 28203169 
17. Peddi P, Ajit NE, Burton GV, El-Osta H. Regression of glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. BMJ case reports 2016, PMID: 28011886 16.
18. El-Osta HE, Shahid K, Mills GM, Peddi P. Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment. OncoTargets and Therapy. 2016; PMID: 27574451. 
19. Chu QD, Zhou M, Medeiros KL, Peddi P, Kavanaugh M, Wu XC. Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy. BMC Cancer.2016; PMID: 27412163  
20. Chu QD, Peddi P. Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast.  Clinical Medicine Insights Oncology 2016; PMID: 27398043. 
21. Chu QD, Zhou M, Medeiros K, Peddi P. Positive surgical margins contribute to the survival paradox between patients with stage IIB/C (T4N0) and stage IIIA (T1-2N1, T1N2a) colon cancer. Surgery 2016. PMID: 27425043 20.
22. Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD, Griffiths E, Greer AH, Yin H, Peddi P, Shackelford RE. Histiocytic Sarcoma as a Secondary Malignancy: Pathobiology, Diagnosis, and Treatment. European Journal of Hematology. 2016: PMID: 26990812. 
23. Su J, Al-delfi FJ, Mills GM, Peddi P. Charcot’s Osteoarthropathy Mimicking an Osteosarcoma of Humerus. BMJ case reports. 2016: PMID: 26744534
24. Shi R, Burton G, Mills GM, Peddi P. Effect of Postmastectomy Radiation on Survival of AJCC pN2/N3 Breast Cancer Patients. Anticancer Research.2016; PMID: 26722052. 
25. Peddi P, Paryani B, Takalkar A, Bundrick P, Ponugupati J, Nair B, El-Osta H. Exceptional Response to Cetuximab Monotherapy in a Patient with Metastatic Oropharyngeal Squamous Cell Carcinoma: A Molecular Insight; OncoTargets and Therapy 2016; PMID: 26929641 
26. Peddi P, Gallagher K.M, Chandrasekharan C, Wang Q, Gonzalez-Toledo E, Nair B.S, Munker R, Mills G.M, and Koshy N.V. Tolosa-Hunt Syndrome in Double-Hit Lymphoma; Case Reports in Oncological Medicine. 2015: PMID: 25918657. 25.
27. Peddi P, Shi R, Nair B.S, Ampil F, Mills G.M and Jafri S.H. Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review. Clinical Medicine Insights: Oncology. 2015; PMID: 25628515 
28. Volodin L, Peddi P, Takalkar A, Comeau J, Shahan J and Hildebrandt C.G. Successful treatment of first and second recurrence of Acute Lymphoblastic Leukemia after Related Allogenic Bone Marrow Transplantation at unusual sites using single dose vincristine followed by Interferon-alpha 2b and GM-CSF. Leuk Lymphoma. 2012; PMID: 23020692 26.
29. El-Osta H, Abdulbaki A, Peddi P, Takalkar A, Cotelingam J, Veillon D, Vargas A, Akkus N and Hildebrandt C.G, Lactic Acidosis and Atrial Tachycardia: An Unusual Presentations of Disseminated Burkitt's lymphoma. Journal of Cancer Therapy. 2012; 3: 589-584. 
30. Peddi P, Slay L.E, Lilien D.L, Fowler M.R, Cotelingam J, Veillon D.M, Ayirookuzhi S, Koshy N, Mills G.M, Munker R.  Metastatic Malignant Melanoma in a Patient with Hodgkin’s Lymphoma in Remission. Journal of Louisiana State Medical Society. J La State Med Soc. 2010; PMID: 20336959. 
31. Peddi P, Loftin C.W, Dickey J.S, Hair J.M, Burns K.J, Aziz K, Francisco D.C, Panayiotidis M.I, Sedelnikova O.A, Bonner  W.M, Winters T.A and Georgakilas A.G. DNA-PKcs deficiency leads to persistence of oxidatively-induced clustered DNA  lesions in human tumor cells, Free Rad. Biol. Med. 2010; PMID: 20193758. 
32. Peddi P, Francisco D.C, Cecil A.M, Hair J.M, Panayiotidis M.I and Georgakilas A.G. Processing of clustered DNA damage in human breast cancer cells MCF-7 with partial DNA-PKcs deficiency. Cancer Letters 2008; PMID: 18550272. 30. Francisco D.C, Peddi P, Hair J.M, Flood B.A, Cecil A.M, Kalogerinis P.T, Sigounas G and Georgakilas A.G. Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and non-malignant MCF-10A cells. Free Radic.  Biol. Med. 2008; PMID: 18005669 
33. Lally B.E, Geiger G.A, Kridel S, Arcury-Quandt A.E, Robbins M.E, Kock N.E, Wheeler K, Peddi P, Georgakilas A.G, Kao G.D and Koumenis C. Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library. Cancer Res. 2007; PMID: 17875720 

POSTERS 

• Patel AN, Shi R, Peddi P, Burton GV. Triple Negative Breast Cancer- Adjuvant chemotherapy use and survival outcomes in stage IA disease. SABCS 2016. San Antonio. P5-14-03. Abstract #850149 
• Samip M, Peddi P, Koshy N, Mills G, Mansour R. Eltrombopag Improves Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. BMT Tandem Meeting 2017. Orlando.  
• Medeiros K, Peddi P, Zhou M, Wu XC, Chu Q. Can Radiation Therapy Adequately Address Positive Surgical Margins in Elderly Women (≥70 Years) With Stage I, ER+ Breast Cancer? 2016 ASCO Annual Meeting. Poster # 164215.
• Gao W, Peddi P, Shi R, Burton G. Survival Outcomes after Adjuvant Radiation in Women ≥ 65 years diagnosed with Ductal Carcinoma In-situ: Analysis of National Cancer Data Base. 2016 ASCO Annual Meeting. Poster # 168802.
• Peddi P, Master S, Pasam A, Ravipati H, Patel A, Dwary A, Shi R, Burton G. Pre-treatment evaluation of LVEF for Breast Cancer Patients Receiving Anthracyclines. Is it Necessary? 2016 ASCO Annual Meeting. ASCO Poster # 164995.
• Su J, Peddi P. Charcot’s Osteoarthropathy Mimicking an Osteosarcoma of Humerus. Presented at Southern Regional Meeting 2016, New Orleans. Poster # 139 
• Jassal V, Neppalli A, Shahid K, Wilkinson B, Peddi P. Radiation Recall in Breast Cancer Patient on Herceptin. The Ray A Barlow Scientific symposium, Shreveport, LA 2015, 
• Shahid K, Gallagher K, Khandelwal K, Koshy N, Peddi P. Acute Myeloid Leukemia Presenting with Spinal Cord Compression. The Ray A Barlow Scientific symposium, Shreveport, LA, 2015 
• Dwary A, Pai S, Master S, Patel A, Koshy N, Mills G, Peddi P. Survival Outcomes in HIV and Non-HIV Burkitts Lymphoma Patients Treated with Rituximab – Hyper CVAD Regimen. The Ray A Barlow Scientific Symposium, Shreveport, LA 2015
• Su J, Peddi P. Pathological Shoulder Fracture with Lytic Mass Associated with Syringomyelia. The Ray A Barlow Scientific symposium, Shreveport, LA, 2015 
• Patel A, Koticha K, Mills G, Peddi P. Transient 20q Deletion in Pernicious Anemia. The Ray A Barlow Scientific symposium, Shreveport, LA, 2015 
• Anand K, Peddi P. Malignant Melanoma presenting as Isolated Pleural Effusion in a patient with Chronic lymphocytic leukemia. The Ray A Barlow Scientific symposium, Shreveport, LA, 2015. 

ORAL PRESENTATIONS: 

• Chu QD, Peddi P, Zhou M, Wu XC Outcome in Real-World Practice for Elderly Patients with Early Breast Cancer. Accepted for Oral Presentation at 12^th Annual Academic Surgical Congress, Las Vegas 2017.  
• Chu QD, Medeiros K, Zhou M, Peddi P, Shokouh-Amiri, Wu XC. Effect of Facility Type on Outcome Following Pancreatectomy for Pancreatic Adenocarcinoma: Analysis of the National Cancer Data Base. Mini-Oral Presentation.  Presented at 12^th World Congress of the International Hepato-Pancreato-Biliary Association. Poster: FP26-02 
• Chu QD, Medeiros K, Zhou M, Peddi P, Shokouh-Amiri, Wu XC. Effect of Facility Type on Outcome Following Pancreatectomy for Pancreatic Adenocarcinoma: Analysis of the National Cancer Data Base. Scientific Session III: Mini Talk Presentation. LA- American College of Surgeons 2015. 
• Chu QD, Medeiros K, Zhou M, Peddi P, Wu XC. Minimal Impact of Co-operative Trial and Sociodemographic Variation of Radiation Therapy Usage in Elderly Patients with stage I, ER+/PR+ Breast Cancer: Analysis of the National Cancer Data.  Scientific session III: Mini-Talk Presentation LA- American College of Surgeons 2015 
• Chu QD, Zhou M, Medeiros K, Peddi P, Kavanaugh M, Wu XC. Inadequate Lymph Nodes Retrieved, Lack of Receipt of Adjuvant Chemotherapy, and Socioeconomic Factors Contribute to the Poor Survival in Stage IIB/C (T4N0) Compared to Stage IIIA (T1-2N2A) Colon Cancer. Scientific session I: Surgical Oncology Oral Presentation. LA- American College of Surgeons 2015.
• Medeiros K, Zhou M, Peddi P, Wu XC, Chu QD. Can Radiation Therapy Adequately Address Positive Surgical Margins in Elderly Women (≥70 years) with Stage I, ER+ Breast Cancer. Scientific session I: Surgical Oncology Oral Presentation. LA American College of Surgeons 2015 
• Peddi P and Francisco D.C. Role of DNA-PKcs in processing of Oxidative clustered DNA lesions in the human breast cancer cells MCF-7. Oral Presentation- East Carolina University-Graduate Research Day, Greenville, NC, USA; 2005. 

ABSTRACTS 

• Singh V, Cupp JA, Peddi P. Is circulating tumor DNA the best surveillance tool for detecting post-adjuvant relapses in stage I-III breast cancer patients. J Clin Oncol 43, 2025; e12505.
• Singh V, Dhaibar H, Peddi P. Real-world outcomes of Sacituzumab Govitecan in breast cancer. J Clin Oncol 42, 2024: e13137.
• Tano SV, Kavanaugh MM, Peddi P, Mansour RP, Shi R, Burton GV. Triple negative breast cancer (TNBC): Analysis of age and stage distribution and survival between African American and Caucasian women in a predominant low-income population. J Clin Oncol 35: e12586. 
• Dwary AD, Gupta A, Burton GV, Peddi P. Primary brain tumor and risk of venous thromboembolism. J Clin Oncol 35, e13518 
• Master S, Koshy N, Peddi P. Eltrombopag Improves Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. BMT Tandem Meetings, Orlando 2017  
• Patel AN, Shi R, Peddi P, Burton GV. Triple Negative Breast Cancer- Adjuvant chemotherapy use and survival outcomes in stage IA disease. SABCS 2016. Abstract: 850149. 
• Medeiros K, Peddi P, Zhou M, Wu XC, Chu Q. Can Radiation Therapy Adequately Address Positive Surgical Margins in Elderly Women (≥70 Years) With Stage I, ER+ Breast Cancer? J Clin Oncol 34, 2016, (Abstract:1045) 6. Gao W, Peddi P, Shi R, Burton G. Survival Outcomes after Adjuvant Radiation in Women ≥ 65 years diagnosed with Ductal Carcinoma In-situ: Analysis of National Cancer Data Base. J Clin Oncol 34, 2016. (Abstract:1058) 7. Peddi P, Master S, Pasam A, Ravipati H, Patel A, Dwary A, Shi R, Burton G. Pre-treatment evaluation of LVEF for Breast Cancer Patients Receiving Anthracyclines. Is it Necessary J Clin Oncol 34, 2016 (Abstract: 6608) 8. Chu QD, Medeiros K, Zhou M, Peddi P, Shokouh-Amiri, Wu XC. Effect of Facility Type on Outcome Following Pancreatectomy for Pancreatic Adenocarcinoma: Analysis of the National Cancer Data Base. Mini-Talk Presentation. LA American College of Surgeons 2015.  
• Chu QD, Medeiros K, Zhou M, Peddi P, Wu XC. Minimal Impact of Co-operative Trial and Sociodemographic Variation of Radiation Therapy Usage in Elderly Patients with stage I, ER+/PR+ Breast Cancer: Analysis of the National Cancer Data.  LA- American College of Surgeons 2015 
• Chu Q, Zhou M, Wu XC, Peddi P, Medeiros K. Minimal impact of cooperative trial and sociodemographic variation of radiation therapy usage in elderly patients (≥ 70 years) with stage I, ER+/PR+ breast cancer: Analysis of the national cancer data base. Annual Meeting of Southern Surgical Southern Association, 2015. Abstract 32. 
• Chu QD, Zhou M, Medeiros K, Peddi P, Kavanaugh M, Wu XC. Inadequate Lymph Nodes Retrieved, Lack of Receipt of Adjuvant Chemotherapy, and Socioeconomic Factors Contribute to the Poor Survival in Stage IIB/C (T4N0) Compared to Stage IIIA (T1-2N2A) Colon Cancer. Oral Presentation. LA- ACS Annual Meeting, January 2015. 
• Medeiros K, Zhou M, Peddi P, Wu XC, Chu QD. Can Radiation therapy adequately address positive surgical margins in elderly women (≥ 70 years) with stage I, ER+ Breast Cancer? Annual Meeting LA- American College of Surgeons and Surgical Association of Louisiana, 2015. Abstract: 135
• Pai S, Master S, Dwary A, Patel A, Shi S, Mills G, Peddi P, Koshy N. Outcomes of American Burkitt's Lymphoma in HIV and Non-HIV Patients Treated with Rituxan-Hyper CVAD Regimen. A Single Center Retrospective Study. Presentation #348.  BMT Tandem Meetings 2016. Honolulu, Hawaii. Poster # 315 
• Chu Q, Medeioris K, Zhou M, Peddi P, Zibari GB, Amiri, HS, Wu XC. Effect of Facility Type on Outcome Following Pancreatectomy for Pancreatic Adenocarcinoma: Analysis of the National Cancer Data Base. Annual Meeting for International Hepato-Pancreato-Biliary Association 2015. 
• Kodali K, Takalkar A, Shi R, Peddi P, Mills G.M and Jafri S.H. SUV max of the most intense lesion on FDGPET/ CT scan at baseline as a potential prognostic factor in stage IV (NSCLC): A retrospective review J Clin Oncol 31, 2013 (Abstract: e19070) 
• Peddi P, Shi R, Ampil F, Nathan C.A, Armaghany T, Mills G.M and Jafri S.H. Cisplatin (CDDP) and radiation versus cetuximab (Cx) and radiation in locally advanced head and neck squamous cell cancer (SCHNC): A retrospective review. J Clin Oncol 30, 2012 (Abstract: e16009) 
• El-Osta H, Peddi P, Veillon D, Takalkar A, Jafri S.H, Mills G.M and Hildebrandt A.G. Rosai-Dorfman disease presenting as Soft Tissue Tumor of the Lower Limb. Southern Regional Meeting Abstracts. New Orleans, LA 2012: Abstract 483; 444. 18. Peddi P, Francisco D.C, Hair J.M, Cecil A.M, Sedelnikova O.A, Winters T.A, Sigounas G and Georgakilas A.G.  Accumulation of complex DNA damage in human breast cancer cells MCF-7 deficient in DNA-PKcs. Proceedings of the 99^th American Association for Cancer Research. San Diego, CA, USA; 2008: 142. 
• Peddi P, Francisco D.C, Hair J.M, Cecil A.M, Sedelnikova O.A, Winters T.A and Georgakilas A.G. Compromised processing of clustered DNA lesions in MCF-7 with partial DNA-PKcs deficiency. Proceedings of the 54th Annual Meeting of the Radiation Research Society. Boston, MA, USA; 2008: 36-37. 
• Peddi P, Francisco D, Hair J, Cecil A, Sedelnikova O, Winters T, Sigounas G, Georgakilas A. Accumulation of complex DNA damage in human breast cancer cells MCF-7 deficient in DNA-PKcs. Cancer Res May 1, 2008, 68; 604 21.
• Peddi P, Francisco D.C, Flood B.A, Sigounas G and Georgakilas A.G. Accumulation of oxidative clustered DNA lesions (OCDLs) in the human breast cancer cells MCF-7. Proceedings of the 53rd Annual Meeting of the Radiation Research Society. Philadelphia, Pennsylvania, USA; 2007: 53. 
• Hair J.M, Peddi P, Francisco D.C, Flood B, Cecil A and Georgakilas A.G. (PS3085) Induction and processing of oxidative clustered DNA lesions in the human breast cancer lines MCF-7, MCF-10A and HCC1937. Proceedings of 13^th International Congress of Radiation Research. San Francisco, CA, USA; 2007: 169-170. 

PRINCIPAL INVESTIGATOR OF IN-HOUSE IRB PROTOCOLS

• 2013-2016: Cisplatin and radiation Vs Cetuximab & radiation in LAHN Cancer
• 2014-2017: Validity of Pretreatment Echo in Patients Treated with Doxorubicin or Trastuzumab
• 2015-2016: Pericardial effusion in malignancy  
• 2015: Incidence of DVT in brain tumors.  

INSTITUTIONAL PRINCIPIAL AND CO- INVESTIGATOR ROLE 

• E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship.  
• NCI-MATCH: ECOG/ACRIN: NCI-Molecular Analysis for Therapy Choice. 
• S1013- A Prospective Study of epidermal growth Factor Receptor Inhibitor-Induced Dermatologic Toxicity: Validation of the functional assessment of cancer therapy-EGFRI 18 (FACT-EGFRI 18) questionnaires for EGFRI- Induced Skin Toxicities ▪ S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple Negative Breast Cancer (TNBC) and/or BRCA Mutation-Associated Breast Cancer 
• NRG003- A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer  
• E5508- Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of  Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC ▪ S0931- EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study ▪ S0820- A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas  and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing  Adenomas of the Colon with Eflornithine and Sulindac (PACES) 
• S1216 – A Phase III randomized trial comparing Androgen deprivation therapy plus TAK-700 with androgen deprivation therapy plus bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer. ▪ N9831 - Phase III Trial of Doxorubicin Cyclophosphamide (AC) followed by weekly Paclitaxel with or without Trastuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer. 
• S1007- A Phase III randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor positive and HER2 negative breast cancer with recurrence score (RS) of 25 or less. ▪ E1Z11: A cohort study to evaluate genetic predictors of aromatase inhibitor musculoskeletal symptoms (AIMSS) ▪ S0702: A prospective observational multicenter cohort study to assess the incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastasis starting zoledronic acid treatment. 
• 09-266-B: Randomized double-blind phase II trial of everolimus versus placebo as adjuvant therapy in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) 
• S1207 – Phase III randomized placebo controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu negative breast cancer ▪ E5508 – Randomized phase III study of maintenance therapy with bevacizumab, pemetrexed or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel and bevacizumab for advanced non-squamous NSCLC.
• S9177: Phase II study of dose adjusted EPOCH +/- rituximab in adults with untreated burkitts lymphoma, c-myc positive diffuse large B cell lymphoma and plasmablastic lymphoma. 
• CALGB 80702: A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer. 
• E1609: A phase III randomized study of adjuvant ipilumumab anti- CTLA4 therapy versus high dose interferon alpha-2B for resected high-risk melanoma. 
• S0226: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for post-menopausal Women with Metastatic Breast Cancer 
• S1014: Phase II Abiraterone acetate treatment for prostate cancer patients with a PSA of more than four following initial androgen deprivation therapy 
• S1013: A prospective study of epidermal growth factor receptor (HER-1/EGFR) inhibitor-induced dermatological toxicity: A validation of the functional assessment of cancer therapy – EGFRI 18 (FACT –EGFR1 18) questionnaire for EGFRI-induced skin toxicities. 
• S8020: A phase III double blind placebo- controlled trial of eflornithine and sulindac to prevent recurrence of high-risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer. 
• E1199: A phase III study of doxorubicin – cyclophosphamide therapy followed by paclitaxel or docetaxel given weekly or every 3 weeks in patients with axillary node-positive breast cancer or high-risk node negative. 
• E5103: A double-blind phase III trial of doxorubicin and cyclophosphamide followed by paclitaxel with bevacizumab or placebo in patients with lymph node positive and high-risk lymph node negative breast cancer. 
• NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer. ▪ PACCT-1: Trial assigning individualized options for treatment: The TAILORx Trial. 
• E2197: A phase III study of doxorubicin / docetaxel vs. doxorubicin / cyclophosphamide for the adjuvant treatment of node positive or high-risk node negative breast cancer. 
• IBCSG 24-02: A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (SOFT) 
• JMA17 R: A phase III randomized double-blind study of letrozole vs. placebo in women with primary breast cancer completing five or more years of adjuvant tamoxifen 
• Z9001: A phase III randomized double-blind study of adjuvant ST1571 (Gleevec) vs. placebo in patients following the resection of primary gastrointestinal stromal tumor (GIST) 
• NSABP B-35: A clinical trial comparing anastrozole with tamoxifen in postmenopausal patients with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy 
• ACES: ASPREE cancer endpoints study. 
• ASPREE: Aspirin in reducing events in the elderly.
• A phase III randomized, double blind, placebo-controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2 negative AI treated, locally advanced or metastatic breast cancer who progressed on or  after mTOR inhibitor based treatments (BELLE3)